STOCK TITAN

[SCHEDULE 13G] Bicara Therapeutics Inc. Passive Investment Disclosure (>5%)

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G

Rhea-AI Filing Summary

T. Rowe Price Investment Management, Inc. reported a passive ownership stake in Bicara Therapeutics Inc. common stock. The firm beneficially owns 3,236,595 shares, representing 5.9% of the outstanding common stock as of December 31, 2025.

T. Rowe Price has sole power to vote and dispose of these 3,236,595 shares and no shared voting or dispositive power. The firm certifies the shares were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of Bicara Therapeutics.

Positive

  • None.

Negative

  • None.





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G



T. Rowe Price Investment Management, Inc.
Signature:Ellen York
Name/Title:Vice President
Date:02/17/2026
Bicara Therapeutics

NASDAQ:BCAX

BCAX Rankings

BCAX Latest News

BCAX Latest SEC Filings

BCAX Stock Data

844.74M
45.06M
Biotechnology
Pharmaceutical Preparations
Link
United States
BOSTON